TPO was previously reported to be among the most mutated genes in PAAD patient tumors in TCGA, suggesting a possible combined influence of epigenetic regulation of this gene and the mutational landscape on treatment response [153]. This evidence concerns the gene TPO and pancreatic adenocarcinoma.